A Randomized Phase 2 Trial to Evaluate the Efficacy of BCL-2 Inhibitor Therapy With Chemotherapy Compared to Chemotherapy Alone in Adult Patients With Newly Diagnosed T-Cell ALL and T-Cell Lymphoblastic Lymphoma

This phase II trial tests the safety and effectiveness of giving chemotherapy with or without venetoclax and/or navitoclax for the treatment of patients with newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL). Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Venetoclax and navitoclax are in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. They may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving chemotherapy with or without venetoclax and/or navitoclax may be effective treatments for patients with newly diagnosed T-ALL or T-LBL.

开始日期2024-08-09

申办/合作机构

National Cancer Institute

NCT06390319 / Not yet recruiting临床2期IIT

SJALL23T: Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

This is a clinical trial testing whether the addition of one of two chemotherapy agents, dasatinib or venetoclax, can improve outcomes for children and young adults with newly diagnosed T-cell acute lymphoblastic leukemia and lymphoma or mixed phenotype acute leukemia.
Primary Objective
To evaluate if the end of induction MRD-negative rate is higher in patients with T-ALL treated with dasatinib compared to similar patients treated with 4-drug induction on AALL1231.
To evaluate if the end of induction MRD-negative rate is higher in patients with ETP or near-ETP ALL treated with venetoclax compared to similar patients treated with 4-drug induction on AALL1231.
Secondary Objectives
To assess the event free and overall survival of patients treated with this therapy.
To compare grade 4 toxicities, event-free survival (EFS) and overall survival (OS) of patients treated with this therapy in induction and reinduction to toxicities of similar patients treated on TOT17.

开始日期2024-05-01

申办/合作机构

St. Jude Children's Research Hospital, Inc.

[+1]

NCT03808610 / Recruiting临床1/2期IIT

Phase I/II Study of the Combination of Low-Intensity Chemotherapy and Venetoclax (ABT-199) in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

This phase I/II trial studies the side effects and best dose of venetoclax and how well it works in combination with low-intensity chemotherapy in patients with B- or T-cell acute lymphoblastic leukemia that has not responded to treatment or that has come back. Venetoclax may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, including vincristine, cyclophosphamide, dexamethasone, rituximab, methotrexate, and cytarabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax with low-intensity chemotherapy may work better in treating patient with B- or T-cell acute lymphoblastic leukemia.

开始日期2019-04-03

申办/合作机构

The University of Texas MD Anderson Cancer Center

[+1]

100 项与奈拉滨相关的临床结果

登录后查看更多信息

100 项与奈拉滨相关的转化医学

登录后查看更多信息

100 项与奈拉滨相关的专利（医药）

登录后查看更多信息

242

项与奈拉滨相关的文献（医药）

2024-04-01·Journal of Oncology Pharmacy Practice

Management of Nelarabine induced neurotoxicity in a child with T-cell acute lymphoblastic lymphoma

Article

作者: Motwani, J ; Karthik, U

Introduction Nelarabine is now increasingly being used for the treatment of relapsed T-cell acute lymphoblastic leukemia/lymphoma, and about 18% of patients experience ≥ grade 3 toxicity. Despite the increasing use of this drug, there are no guidelines for managing its neurotoxicity. We would like to share our experience with one such case. Case Report A sixteen-year-old girl with T-lymphoblastic lymphoma received Nelarabine as part of her relapse treatment. Three weeks post-treatment, patient presented with worsening encephalopathy, bulbar palsy, and seizures. Management and outcome After a detailed evaluation, Nelarabine neurotoxicity was strongly considered and was managed with a combination of steroids, intravenous immunoglobulin, and aminophylline, with almost complete recovery starting at 72 hours of treatment initiation. Discussion Despite the increasing use of this drug, guidelines for the management of the neurological adverse effects of Nelarabine are lacking. The above-mentioned combination of drugs worked for our patient, but larger numbers are needed to validate this as an approved treatment regimen.

2024-03-01·Environmental Toxicology

Novel disulfidptosis‐derived gene blueprint stratifying patients with breast cancer

Article

作者: Tang, Xiaojiang ; Ping, Baohua ; Liu, Yang ; Zhou, Yuhui

AbstractIntroductionBreast cancer remains the predominant cancer among females, accounting for about 24.2% of all cancer cases. Alarmingly, it is the primary cause of cancer‐related mortality in women under 45.MethodsThis research analyzed RNA sequencing data from 1082 TCGA‐BRCA and 107 GSE58812 breast cancer patients. Single‐cell RNA data from five patients in the GSE118389 data set were also studied. Using Random forest and COX regression, we developed a prognostic model. Pathway analysis employed GSVA and GO, while immune profiles were assessed via ssGSEA and MCPcounter. Mutation patterns utilized maftools, and drug sensitivity scores were derived from the GDSC database with oncoPredict.ResultsAnalysis of the GSE118389 data set identified three distinct cell types: immune, epithelial, and stromal. P53 and VEGF were notably enriched. Five key genes (TMEM251, ADAMTSL2, CDC123, PSMD1, TLE1) were pinpointed for their prognostic significance. We introduced a disulfidptosis‐associated score as a novel risk factor for breast cancer prognosis. Survival outcomes varied significantly between training and validation sets. Comprehensive immune profiling revealed no difference in activated CD8‐positive T cells between risk groups, but a positive correlation of NK cells, neutrophils, cytotoxic lymphocytes, and monocytic cells with the riskscore was noted. Importantly, a negative association between the drug Nelarabine and riskscore was identified.ConclusionThis research underscores the significance of a disulfidptosis‐associated gene signature in breast cancer prognosis.

2024-03-01·International Journal of Hematology

Nelarabine-containing salvage therapy and conditioning regimen in transplants for pediatric T-cell acute lymphoblastic leukemia and lymphoma

Article

作者: Seki, Masafumi ; Yanagi, Masato ; Mori, Makiko ; Oshima, Koichi ; Honda, Mamoru ; Arakawa, Yuki ; Mitani, Yuichi ; Koh, Katsuyoshi ; Fukuoka, Kohei

Therapy for relapsed or refractory (r/r) T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in children is challenging, and new treatment methods are needed. We retrospectively analyzed eight patients with r/r T-ALL (five patients) and T-LBL (three patients) who were treated with nelarabine (NEL) plus etoposide, cyclophosphamide, and intrathecal therapy, administered 3 days apart. Five patients achieved a complete response, and the other three achieved a partial response (PR). All patients underwent hematopoietic stem cell transplantation (HSCT) after two cycles of treatment, except for one patient who received one cycle. Three patients who had previously received HSCT were treated with reduced-intensity conditioning regimens, including fludarabine, melphalan, and NEL; one survived for over 5 years after the second HSCT. Grade 2 neuropathy occurred in one patient, but other severe toxicities commonly associated with NEL were not observed during NEL administration in combination with chemotherapy. The 2-year overall survival and event-free survival rates were 60.0% and 36.5%, respectively. The addition of NEL to reinduction chemotherapy was useful in achieving remission and did not lead to excessive toxicity. In addition, a conditioning regimen, including NEL, appeared to be effective in patients who had previously undergone HSCT.

项与奈拉滨相关的新闻（医药）

2024-04-08

·BioSpace

Shorla Oncology Announces FDA Filing Acceptance of New Drug Application to Treat Certain Forms of Leukemia and Other Cancers

Second FDA Acceptance for an NDA Filing by Shorla Oncology Announced in 2024 New Oral Liquid Drug from the U.S.-Ireland Pharmaceutical Company Slows or Stops the Growth of Certain Types of Leukemia and Other Cancers CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s New Drug Application (NDA) for SH-201, the first palatable oral liquid of the related chemotherapeutic agent to treat certain forms of leukemia and other cancers. The Agency assigned a Prescription Drug User Fee Act (“PDUFA”) action date of November 30, 2024. “With this NDA acceptance for SH-201, we are a step closer to providing an alternative treatment to thousands of U.S. patients diagnosed with leukemia and other cancers who do not currently have the option of an oral liquid,” said Sharon Cunningham, Chief Executive Officer and Co-Founder of Shorla Oncology. “Submitting this drug to the FDA for review is more than just a milestone for our company, it’s an important moment for all those impacted by this disease including patients, caregivers and clinicians.” SH-201 is an oral liquid treatment that slows or stops the growth of certain forms of leukemia and other cancers such as: Chronic Myeloid Leukemia - Affects approximately 9,280 new patients each year in the U.S.1 Acute Lymphoblastic Leukemia - Impacts approximately 6,550 new patients each year in the U.S.2 “The FDA’s action today ensures that Shorla is well positioned to bring this innovative oral drug to market,” said Orlaith Ryan, Chief Technical Officer and Co-Founder of Shorla Oncology. “SH-201 addresses key areas of unmet need by providing a palatable liquid treatment option for patients suffering with cancer.” This milestone for SH-201 follows acceptance to in January of this year for SH-105, a novel, differentiated ready-to-dilute formulation for the treatment of adenocarcinoma of the breast or ovary. It is progressing through FDA review. The company recently raised $35 million in Series B funding that has allowed Shorla to accelerate the growth of its oncology portfolio. Last year, the company launched Nelarabine for the treatment of T-cell Leukemia and JYLAMVO, the first and only oral methotrexate solution approved in the United States for use in adults for the treatment of acute lymphoblastic leukemia and other indications. About SH-201 SH-201 is the first palatable oral liquid of the related chemotherapeutic agent in the U.S. SH-201 is an oral liquid treatment that slows or stops the growth of certain forms of leukemia (such as acute lymphoblastic leukemia and chronic myeloid leukemia) and other cancers. About Shorla Oncology Established in 2018 by Sharon Cunningham and Orlaith Ryan, Shorla Oncology is a privately held, U.S. and Ireland-based commercial stage specialty pharmaceutical company with an advanced pipeline of innovative oncology drugs for orphan and pediatric cancers. The company concentrates on indications where existing treatments are limited, in shortage or the drug applications are inadequate for the target population. Shorla's growing portfolio brings accessible, affordable and life-saving treatments to patients, delivering a major contribution to patient care. The company currently markets two products, Nelarabine for the treatment of T-cell Leukemia and JYLAMVO for the treatment of acute lymphoblastic leukemia and other indications. Additionally, the company has two NDAs under FDA review with a view to additional launches within the next twelve months. For further information, please visit . _________________________ 1, 2 American Cancer Society. Cancer Facts & Figures, 2024 View source version on businesswire.com: Contacts Media Dawn Fallon New Dawn Communications LLC dfallon@newdawncomms.com 732-771-7808 Source: Shorla Oncology View this news release online at:

上市批准申请上市

2024-04-08

·Pharmaceutical Technology

FDA accepts Shorla’s oral liquid leukaemia drug NDA

The FDA has set a Prescription Drug User Fee Act (PDUFA) date of 30 November 2024. Credit: Tada Images via Shutterstock. A new drug application (NDA) from US-Ireland speciality pharmaceutical company Shorla Oncology has been accepted by the US Food and Drug Administration (FDA) for SH-201, an oral version of the related leukaemia chemotherapy drug. The regulatory agency will give a decision on the approval on 30 November 2024 under the Prescription Drug User Fee Act. Shorla obtained the rights to SH-201, previously named PIP-101, in July 2023 from an unnamed developer. Under the agreement, the developer was to continue to manufacture the drug until Shorla received an NDA. Shorla will now be responsible for the launch, commercialisation and sales of SH-201 in the US. SH-201 is an oral liquid drug, making the treatment accessible to patients who may struggle with taking tablets or other dosage forms. It slows or stops the growth of certain forms of leukaemia, including chronic myeloid leukaemia and acute lymphoblastic leukaemia. See Also: J&J and Legend’s Carvykti scores early line approval for MM by FDA FDA approves Daiichi Sankyo-AstraZeneca’s Enhertu for solid tumours According to a report on GlobalData’s Pharma Intelligence Center, there will be 17,562 cases of CML in the eight major markets (US, UK, Spain, France, Italy, Germany, Canada, and Japan) in 2030. GlobalData is the parent company of Pharmaceutical Technology. The company is headquartered in Ireland and has operations in the US. In October 2023, Shorla received $35m in Series B funding round led by Kurma Partners’ Growth Opportunities Fund to boost its oncology portfolio growth by advancing drug candidates such as SH-201. In March 2023, the FDA granted approval for Shorla’s Nelarabine injection (SH-111), an oncology drug, to treat T-cell leukaemia, an aggressive blood and bone marrow cancer that progresses quickly. The regulatory approval, which was indicated for T-cell lymphoblastic lymphoma (T-LBL) and T-cell acute lymphoblastic leukaemia (T-ALL), was the company’s first product to receive approval in the US market. Shorla added to its oncology portfolio by acquiring the oncology and autoimmune drug Jylamvo (methotrexate) from Therakind for commercialisation in the US market in October 2023, approved in the US to treat adults with acute lymphoblastic leukaemia, mycosis fungoides, relapsed or refractory non-Hodgkin lymphoma, rheumatoid arthritis, and severe psoriasis. In the announcement accompanying the NDA, Shorla’s CEO Sharon Cunningham said: “With this NDA acceptance for SH-201, we are a step closer to providing an alternative treatment to thousands of US patients diagnosed with leukaemia and other cancers who do not currently have the option of an oral liquid.”

上市批准申请上市引进/卖出

2024-03-06

·米内网

正大天晴火力全开！拿下18个重磅首仿，77款1类新药来势汹汹，17款新药上市可期

精彩内容步入2024年，正大天晴药业研发进展不断：拿下艾曲泊帕乙醇胺首仿，达雷妥尤单抗生物类似药报临床......过去的2023年是公司创新产品硕果累累的一年：1款1类新药、3款生物类似药获批，3款1类新药申报NDA，30余款1类新药申报IND等。目前正大天晴药业在国内有90款新药（77款1类新药）处于申报临床及以上阶段，17款处于NDA或III期临床阶段；仿制药方面，2018年至今拿下18个重磅首仿，目前过评品种数已达63个（23个首家），此外22个新分类申报品种在审。77款1类新药霸屏！猛攻1700亿市场近年来，正大天晴药业通过自主研发、并购投资、外部引进等方式，不断拓宽在研创新产品管线，推动公司从“肝病为主”向“两核多强”转变，形成了以肝病用药、抗肿瘤药为主体，消化系统、呼吸系统、骨骼肌肉系统等多领域协同发展的研发格局。目前正大天晴药业有4款1类新药获批上市，包括异甘草酸镁注射液（天晴甘美）、盐酸安罗替尼胶囊（福可维）、派安普利单抗注射液（安尼可）及艾贝格司亭α注射液（亿立舒），其中天晴甘美、福可维2022年在中国城市公立医院、县级公立医院、城市社区中心及乡镇卫生院（简称中国公立医疗机构）终端的销售额分别超过20亿元、30亿元。米内网数据显示，含引进的产品在内，目前正大天晴药业在国内还有90款新药（不含已有批文产品）处于申请临床及以上阶段，其中有77款为1类新药，创新产品管线处于行业前列。正大天晴药业国内在研新药来源：米内网综合数据库90款新药中，8款已申报上市，包括TQ-B3101胶囊（ALK/MET/ROS1抑制剂）、TQ-B3139胶囊（c-Met/ALK/ROS抑制剂）、TQB2450注射液（PD-L1单抗）、TQ-B3525片（PI3Kα/δ抑制剂，国内暂无同靶点药物获批）、格舒瑞昔片（KRAS G12C抑制剂，国内暂无同靶点药物获批）5款1类新药，以及帕妥珠单抗注射液（国内暂无生物类似药获批）、利拉鲁肽注射液2款生物类似药。此外，9款新药已步入III期临床，包括TQB3616胶囊（CDK4/6抑制剂）、抗菌肽PL-5喷雾剂（抗菌肽，国内暂无同类产品获批）、AL2846胶囊（c-Met抑制剂）、TQB3823片（PARP1/2抑制剂）、lanifibranor片（PPAR激动剂）、TQB3454片（IDH1抑制剂）6款1类新药，以及德谷胰岛素注射液（国内暂无国产企业获批）、司美格鲁肽注射液（国内暂无国产企业获批）2款生物类似药。从治疗领域看，90款新药涵盖抗肿瘤和免疫调节剂（抗肿瘤、自身免疫等）、消化系统及代谢药（糖尿病及NASH）、全身用抗感染药物（丙肝、乙肝等）、呼吸系统等治疗领域，其中抗肿瘤和免疫调节剂占比超过60%，涉及小分子抑制剂、单抗、双抗、ADC等药物形式。米内网数据显示，2022年中国公立医疗机构终端抗肿瘤和免疫调节剂销售额超过1700亿元。拿下18个重磅首仿！22个新品在路上作为传统药企向创新研发转型的代表企业之一，正大天晴药业素有“首仿之王”的称谓。2018年至今，正大天晴药业新获批仿制药数量超过40个，其中有18个为首仿（含剂型首仿），涵盖抗肿瘤和免疫调节剂、消化系统及代谢药、杂类、血液和造血系统药物等治疗领域。2018年至今正大天晴药业获批上市的首仿（含同日获批）来源：米内网中国申报进度（MED）数据库18款首仿涉及了多款全球超10亿美元的重磅品种，如利伐沙班、泊马度胺、艾曲泊帕、西格列汀、托法替布、仑伐替尼、达比加群酯、伏硫西汀等，原研产品2022年全球销售额分别超过70亿美元、30亿美元、20亿美元、20亿美元、10亿美元、10亿美元、10亿美元、10亿美元等。此外，目前正大天晴还有22个仿制药（以药品名称计）以新注册分类申报且在审，获批生产后将视同通过一致性评价。若以通用名药品计，则上述药品2022年在中国公立医疗机构终端的销售规模合计超过100亿元。正大天晴药业新注册分类申报且在审的品种来源：米内网中国申报进度（MED）数据库9个品种在国内暂无首仿（含剂型首仿）获批上市，包括奥贝胆酸片、注射用醋酸地加瑞克、血管紧张素Ⅱ注射液、奈拉滨注射液、酒石酸阿福特罗雾化吸入溶液、右兰索拉唑肠溶胶囊、乌美溴铵维兰特罗粉吸入剂、糠酸氟替卡松维兰特罗粉雾剂(Ⅱ)、糠酸氟替卡松维兰特罗粉雾剂(Ⅰ)。63个过评品种亮眼！9大品种备战集采截至目前，正大天晴药业已有63个品种通过/视同通过一致性评价。其中，23个品种为国内首家过评，艾曲泊帕乙醇胺片、依维莫司片、吸入用氯醋甲胆碱、注射用多黏菌素E甲磺酸钠、氢溴酸伏硫西汀片、甲磺酸仑伐替尼胶囊、泊马度胺胶囊、氟维司群注射液等为国内首仿+首家过评。正大天晴药业已过评品种注：带*为首家/独家过评，加粗代表国采中选来源：米内网一致性评价进度数据库从治疗领域上看，63个过评品种涵盖10个治疗大类，主要集中在抗肿瘤和免疫调节剂（20个）、消化系统及代谢药（13个）、全身用抗感染药物（13个）。米内网数据显示，上述3个治疗大类2022年中国公立医疗机构终端的销售额均超过1500亿元。在已落地执行的八批九轮化药集采中，正大天晴药业分别有3个、1个、3个、5个、7个、6个、1个、3个品种中标，合计29个品种。此外，目前公司已过评但暂未纳入集采的品种有19个。正大天晴药业已过评且暂未纳入国采的品种注：标红代表满足5家及以上的竞争条件来源：米内网综合数据库9个已满足5家及以上的充分竞争条件，包括艾曲泊帕乙醇胺片、泊沙康唑注射液、哌柏西利胶囊、沙库巴曲缬沙坦钠片、索磷布韦片、磷酸西格列汀片、氢溴酸伏硫西汀片、注射用福沙匹坦双葡甲胺、阿瑞匹坦胶囊。资料来源：米内网数据库等注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。数据统计截至3月4日，如有疏漏，欢迎指正!本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

生物类似药临床3期上市批准临床申请

100 项与奈拉滨相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D05134	奈拉滨	L01BB07	DB01280

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
T细胞淋巴瘤	加拿大	Novartis AG	2007-10-20
急性淋巴细胞白血病	日本	Novartis Pharma KK	2007-10-19
T细胞急性淋巴细胞白血病/淋巴瘤	日本	Sandoz Pharmaceuticals AG	2007-10-19
前体T淋巴细胞白血病淋巴瘤	美国	Sandoz, Inc.	2005-10-28

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
T细胞急性淋巴细胞白血病/淋巴瘤	临床3期	中国	正大天晴药业集团南京顺欣制药有限公司	2024-03-05
慢性淋巴细胞白血病	临床3期	美国	Novartis AG	-
小儿淋巴母细胞非霍奇金淋巴瘤	临床1期	美国	National Cancer Institute	1997-06-01
前体T淋巴细胞白血病淋巴瘤	临床1期	-	National Cancer Institute	1997-06-01
复发性 B 型急性淋巴细胞白血病	临床1期	美国	National Cancer Institute	1997-06-01
难治性血液恶性肿瘤	临床1期	美国	National Cancer Institute	1997-06-01
难治性血液恶性肿瘤	临床1期	-	National Cancer Institute	1997-06-01
慢性淋巴细胞白血病	临床1期	美国	Novartis AG	-
小儿淋巴母细胞非霍奇金淋巴瘤	药物发现	-	National Cancer Institute	1997-06-01
复发性 B 型急性淋巴细胞白血病	药物发现	-	National Cancer Institute	1997-06-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


GRAALL-2014/T (ASH2023)	临床2期	前体T淋巴细胞白血病淋巴瘤巩固	325	Nelarabine	(簾鑰淵醖醖鹽艱願鑰顧) = 鑰壓積憲壓鬱廠鏇簾餘鹽艱範繭觸窪鹹選衊構 (淵淵築遞簾廠選醖簾繭, 20 ~ 37) 更多	-	2023-12-11
Pubmed	临床1期	肿瘤	-	Nelarabine	(窪選廠觸餘簾願構繭齋) = 淵範顧夢網鏇憲鬱蓋壓廠衊壓窪繭顧網艱網憲 (衊齋簾糧壓選繭範膚艱 ) 更多	-	2022-11-29
EHA2019	临床4期	T细胞急性淋巴细胞白血病/淋巴瘤	118	Nelarabine	(鹹淵憲築膚鬱蓋壓築簾) = 艱鬱廠鏇網衊餘遞鹹積遞顧簾廠製製憲簾淵夢 (鑰製製醖願積積觸鑰獵 ) 更多	-	2019-06-16
NCT00501826 (ASH2020) 人工标引	临床2期	前体T淋巴细胞白血病淋巴瘤 \| 复发性T淋巴母细胞淋巴瘤一线	96	Peg-Asparaginase+Nelarabine	(壓襯鑰鏇餘獵醖糧繭選) = 齋鬱衊壓餘壓製餘齋選鬱鬱憲築膚顧淵窪製鬱 (鹽鏇鏇鬱艱構蓋醖壓選 ) 更多	积极	2020-11-05
				Peg-Asparaginase+Nelarabine (T-ALL)	(艱鹽廠繭獵廠選淵築鹹) = 鬱範願範廠憲夢構顧網艱觸鏇襯餘餘壓構衊鹹 (膚鑰廠獵選鏇鏇製鏇糧 )
ASH2023	N/A	前体T淋巴细胞白血病淋巴瘤	133	Nelarabine (NEL)	(壓鏇齋鹹製網鹹餘淵襯) = 築憲築蓋網鹹觸製餘艱蓋壓鏇艱鹽廠選遞網鹽 (獵鏇夢積網觸齋壓齋鬱 )	-	2023-12-11
				Pegylated Asparginase (PEG)	(壓鏇齋鹹製網鹹餘淵襯) = 積鹽鬱夢鑰鬱淵夢齋積蓋壓鏇艱鹽廠選遞網鹽 (獵鏇夢積網觸齋壓齋鬱 )
EHA2022	N/A	T细胞急性淋巴细胞白血病/淋巴瘤	120	HyperCVAD + Nelarabine	選鹹願夢製積膚網鬱繭(醖築壓廠憲鬱壓鬱遞餘) = elevated liver enzymes in 25 pts (21%) 鬱蓋築觸糧醖願願廠齋 (願選願獵觸獵製窪選艱 ) 更多	-	2022-05-12
				HyperCVAD + Nelarabine + PEGylated Asparaginase
NCT00408005 (COG AALL0434, ASCO2018)	临床3期	肿瘤	1,895	Nelarabine	(衊壓選淵鹹醖蓋窪鏇積) = 製醖憲獵鑰糧繭構製獵醖網繭範網鏇積遞鏇鑰 (夢鑰夢獵窪願鏇餘願鬱, 2.2) 更多	积极	2018-06-01
				No Nelarabine	(衊壓選淵鹹醖蓋窪鏇積) = 網憲簾鏇簾窪艱鹹憲蓋醖網繭範網鏇積遞鏇鑰 (夢鑰夢獵窪願鏇餘願鬱, 2.5)
EHA2015	N/A	难治性 T 急性淋巴细胞白血病	506	Nelarabine	選鬱襯遞鹽鏇膚廠遞簾(窪襯顧憲淵糧夢繭廠夢) = 範積範積鹽膚願顧鹽壓鏇鏇範觸願壓餘鑰窪艱 (廠繭鹽衊鏇襯顧鑰齋淵 )	-	2015-05-21
EHA2019	N/A	前体T淋巴细胞白血病淋巴瘤	9	Nelarabine	(遞觸蓋遞鹹淵齋觸窪繭) = 蓋築憲鏇網淵積積襯構願糧醖鬱鏇憲鑰構壓範 (選蓋淵醖廠觸艱願膚築 ) 更多	-	2019-05-16
NCT00408005 (AALL0434, Pubmed \| J Urol) 人工标引	临床3期	前体T淋巴细胞白血病淋巴瘤	659	Berlin-Frankfurt-Muenster +Nelarabine	(鑰獵夢遞齋衊醖餘構構) = 觸膚觸艱膚繭觸獵餘餘遞築膚鏇積夢襯壓齋膚 (鬱鏇窪襯選齋獵鏇簾壓, 2.4)	优效	2020-10-01
				Berlin-Frankfurt-Muenster	(鑰獵夢遞齋衊醖餘構構) = 觸襯餘簾願淵繭窪餘醖遞築膚鏇積夢襯壓齋膚 (鬱鏇窪襯選齋獵鏇簾壓, 2.7)